Skip to main content
Fig. 2 | Journal of Hematology & Oncology

Fig. 2

From: Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair

Fig. 2

EDO-S101 induces potent DNA damage and histone acetylation. a Dose and time response of different proteins implicated in the DNA damage response pathway analyzed on the MM1S cell line. b Dose response of different proteins implicated in the DNA damage response pathway on RPMI-8226 and JJN3 cell lines. c Comet assay on the MM1S cell line after treatment with EDO-S101 as compared with untreated cells. Images are representatives of at least 20 captures performed in two independent experiments. Mean tail moment was calculated at different time points using the OpenComet software. d Dose response (48 h) of acetylated proteins after EDO-S101 treatment in MM1S, RPMI-8226, and JJN3 cell lines. e Dose response of proteins implicated in DNA damage repair and acetylation after 48 h of MM1S treatment with EDO-S101 or bendamustine

Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us